Voyageur PharmaceuticalsVYYRF +7.71%18 Net Margin % is -3,278.57% as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 953 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks worse than 98.85% on this metric.
The historical rank and industry rank for Voyageur Pharmaceuticals's Net Margin % or its related term are showing as below:
VYYRF'
s Net Margin % Range Over the Past 10 Years
Min: -29441.67 Med: -29441.67 Max: -10780.65
Current: -10780.65
VYYRF's Net Margin % is ranked worse than 98.85% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs VYYRF: -10780.65
Voyageur Pharmaceuticals (OTCPK:VYYRF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Voyageur Pharmaceuticals Net Margin % Related Terms
Voyageur Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyageur Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Voyageur Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyageur Pharmaceuticals (VYYRF) has a Net Margin % of -3,278.57% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #942 out of 953 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Voyageur Pharmaceuticals' Net Margin % too high?
Voyageur Pharmaceuticals' current Net Margin % is -3,278.57%. Based on the distribution chart, Voyageur Pharmaceuticals ranks #942 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #942 out of 953 companies for Net Margin %. This places Voyageur Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Voyageur Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current Net Margin % is -3,278.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current Net Margin % of -3,278.57%. The current Net Margin % is -3,278.57%. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current Net Margin % is -3,278.57% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score
Get the complete analysis for VYYRF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYYRF has been successfully added to your 
